TIMI 14

OBJECTIVE: To evaluate the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy among patients presenting with ST elevation myocardial infarction.

View/Download
_______________________________________________________________________________

  1. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Antman EM, Giugliano RP, Gibson CM, et al. Circulation 1999;99:2720-32.
    | Abstract | Request Reprints |

  2. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Antman EM, Gibson CM, de Lemos JA, et al. Eur Heart J 2000;21:1944-53.
    | Abstract | Request Reprints |

  3. d flow is Non-culprit blooan independent correlate of ECG injury patterns after thrombolytic therapy: a TIMI 14 substudy.de Lemos JA, Antman EM, Giugliano RP, Coulter SA, McCabe CH, Lambrew C, Ghali M, Gibson CM. Circulation 1998;98 (Suppl I):I-826.
    | Request Reprints |

  4. Abciximab + tPA improves coronary flow in a wide range of subgroups: results from TIMI 14.Giugliano RP, Antman EM, McCabe CH, Anderson KM, Adgey AA, Kleiman NS, Ghali M, Van de Werf F, Braunwald E. Circulation 1998;98 (Suppl I):I-560.
    | Request Reprints |

  5. Factors associated with major hemorrhage during reperfusion therapy in acute myocardial infarction: A TIMI 14 substudy. Giugliano RP, Antman EM, McCabe CH, Menown IBA, Kleiman NS, Ghali M, Coussement PK, Braunwald E. J Am Coll Cardiol 1999;33 (Suppl A):398A.
    | Request Reprints |
  6. Emergency room infusion of abciximab speeds up reperfusion in acute myocardial infarction eligible for primary PTCA. Verheugt FWA, Ohman EM, Antman EM. J Am Coll Cardiol 1999;33 (Suppl A):354A.
    | Request Reprints |

  7. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. Gibson CM, Murphy S, Menown IB, et al. J Am Coll Cardiol 1999;34:1403-12.
    | Abstract | Request Reprints |

  8. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. Gibson CM, Ryan KA, Murphy SA, et al. J Am Coll Cardiol 1999;34:974-82.
    | Abstract | Request Reprints |

  9. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Coulter SA, Cannon CP, Ault KA, et al. Circulation 2000;101:2690-5.
    | Abstract | Request Reprints |

  10. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. De Lemos JA, Antman EM, Giugliano RP, et al. Am Heart J 2000;140:373-8.
    | Abstract | Request Reprints |

  11. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. de Lemos JA, Antman EM, Morrow DA, et al. Clin Chim Acta 2000;298:85-97.
    | Abstract | Request Reprints |

  12. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.de Lemos JA, Antman EM, Gibson CM, et al. Circulation 2000;101:239-43.
    | Abstract | Request Reprints |

  13. Resolution of ST-segment elevation correlates with infarct related artery patency and flow after thrombolytic therapy. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, Gibson CM, Braunwald E for the Thrombolysis in Myocardal Infarction (TIMI) 14 Investigators. Am J Cardiol 2000; 85: 299-304.
    | Request Reprints |

  14. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Llevadot J, Giugliano RP, McCabe CH, et al. Am J Cardiol 2000;85:1409-13.
    | Abstract | Request Reprints |

  15. Adjunctive stenting is associated with the development of Q-waves in acute MI patients: a TIMI 14 substudy. Gibson CM, Murphy SA, Marble SJ, Schuhwerk K, de Lemos JA. Circulation 2000; 102(Suppl II): II-434.
    | Request Reprints |

  16. Single-lead ST-segment resolution to predict epicardial flow following fibrinolytic therapy: a useful bedside tool in acute mycoardial infarction. Cooper HA, de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM. Circulation 2001;104 (Suppl II):II-785.
    | Request Reprints |

  17. Relation between time-to-pharmacologic reperfusion and the probability of achieving complete ST-segment resolution in ST elevation myocardial infarction.Cooper HA, de Lemos JA, Murphy SA, McCabe CH, Schuhwerk KC, Antman EM, Braunwald E. J Am Coll Cardiol 2001; 37 (Suppl.A): 339A.
    | Request Reprints |

  18. Cocaine induced myocardial infarction is associated with reduced microvascular perfusion. Gibson CM, Murphy SA, Kraimer N, Pai R, Weisberg S, Marble SJ, Angeja BG, de Lemos J, Hollander JE, Weber J. Circulation 2001;104 (Suppl II):II-728.
    | Request Reprints |

  19. The impact of embolization protection on angiographic parameters in PCI with stenting in AMI. Sutsch G, Gibson CM, Murphy SA, Amann FW. Eur Heart J 2001;22 (Abstr suppl):119.
    | Request Reprints |

  20. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. de Lemos JA, Morrow DA, Gibson CM, et al. Am J Cardiol 2001;88:353-8.
    | Abstract | Request Reprints |

  21. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. de Lemos JA, Gibson CM, Antman EM, et al. Am Heart J 2001;141:592-8.
    | Abstract | Request Reprints |

  22. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Gibson CM, de Lemos JA, Murphy SA, et al. Circulation 2001;103:2550-4.
    | Abstract | Request Reprints |

  23. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction.Gibson CM, Kirtane AJ, Murphy SA, et al. Catheter Cardiovasc Interv 2001;53:6-11.
    | Abstract | Request Reprints |

  24. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Gibson CM, Murphy SA, Marble SJ, et al. Am J Cardiol 2001;87:450-3, A6.
    | Abstract | Request Reprints |

  25. Aging of intracoronary thrombus due to delayed time-to-reperfusion increases ischemic and angiographic complications in acute myocardial infarction. Giri S, Gibson CM, Eisenhauer A, Kuntz R, Rogers C, Murphy S, Mitchel J, Antman EM, Simon DI. J Am Coll Cardiol 2002;39 (Suppl A):281A.
    | Request Reprints |

  26. Electrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarction. Marks DS, Gudapati SB, Kleczka JF, Murphy S, Cannon CP, Braunwald E. J Am Coll Cardiol 2002;39 (Suppl A):331A.
    | Request Reprints |

  27. Comparison of the frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A TIMI 14 and TIMI 9 substudy. Murphy SA, Giugliano RP, Wong GC, Cannon CP, Antman EM, Gibson CM.J Am Coll Cardiol 2002;39 (Suppl A):279A.
    | Request Reprints |

  28. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Angeja BG, de Lemos J, Murphy SA, et al. Am Heart J 2002;144:649-56.
    | Abstract | Request Reprints |

  29. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. Angeja BG, Kermgard S, Chen MS, et al. J Thromb Thrombolysis 2002;13:133-9.
    | Abstract | Request Reprints |

  30. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Antman EM, Cooper HA, Gibson CM, et al. Eur Heart J 2002;23:928-33.
    | Abstract | Request Reprints |

  31. Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration.Cooper HA, de Lemos JA, Morrow DA, et al. Am Heart J 2002;144:790-5.
    | Abstract | Request Reprints |

  32. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Antman EM, Cooper HA, Gibson CM, et al. Eur Heart J 2002;23:928-33.
    | Abstract | Request Reprints |

  33. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. Murphy SA, Dauterman K, de Lemos JA, et al. Am Heart J 2003;146:42-7.
    | Abstract | Request Reprints |


  34. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Shimpo M, Morrow DA, Weinberg EO, et al. Circulation 2004;109:2186-90.
    | Abstract | Request Reprints |

 

 

 

Home | Trials | Core Laboratories | Services | Publications | Education | Funding | Contact Us |

© 2009 All Rights Reserved TIMI Study Group